R J McDonald1, J S McDonald2, D F Kallmes2,3, V T Lehman2, F E Diehn2, J T Wald2, K R Thielen2, A Dispenzieri4, P H Luetmer2. 1. From the Departments of Radiology (R.J.M., J.S.M, D.F.K., V.T.L., F.E.D., J.T.W., K.R.T., P.H.L.) mcdonald.robert@mayo.edu. 2. From the Departments of Radiology (R.J.M., J.S.M, D.F.K., V.T.L., F.E.D., J.T.W., K.R.T., P.H.L.). 3. Neurosurgery (D.F.K.). 4. Hematology (A.D.), College of Medicine, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND AND PURPOSE: The role of vertebroplasty in patients with myeloma remains relatively undefined. Accordingly, we sought to better define the efficacy of vertebroplasty for myeloma-associated fractures and determine the effect of procedure timing relative to the initiation of systemic therapy on outcomes and complication rates. MATERIALS AND METHODS: Clinical, laboratory, and medication data were retrieved for 172 patients with multiple myeloma treated with vertebroplasty since October 2000. Quantitative outcome data (Roland-Morris Disability Questionnaire [scale, 0-24] and the Numeric Rating Scale [0-10] for pain at rest and with activity) were collected immediately pre- and postoperatively and at 1 week, 1 month, 6 months, and 1 year following vertebroplasty. Patients with ≥50% improvement on the Numeric Rating Scale and ≥40% improvement on the Roland-Morris Disability Questionnaire were classified as "responders." Peri- and postoperative complications were also collected. RESULTS: Significant median improvement in the Roland-Morris Disability and rest and activity Numeric Rating Scale scores (15, 2, and 6 points, respectively; P < .0001) persisted at 1 year without significant change from the immediate postoperative scores (P > .36). Patients on systemic therapy at the time of vertebroplasty were more likely to achieve "responder status," compared with patients not on systemic therapy, for the Numeric Rating Scale pain at rest score (P < .01) and the Roland-Morris Disability Questionnaire score (P < .003), with no difference in complication rates (χ2 = 0.17, P = .68). CONCLUSIONS: Vertebroplasty is an effective therapy for patients with myeloma with symptomatic compression fractures. Favorable outcomes are more likely to be achieved when spinal augmentation is performed after systemic therapy is initiated. Complication rates were not affected by the timing of systemic therapy.
BACKGROUND AND PURPOSE: The role of vertebroplasty in patients with myeloma remains relatively undefined. Accordingly, we sought to better define the efficacy of vertebroplasty for myeloma-associated fractures and determine the effect of procedure timing relative to the initiation of systemic therapy on outcomes and complication rates. MATERIALS AND METHODS: Clinical, laboratory, and medication data were retrieved for 172 patients with multiple myeloma treated with vertebroplasty since October 2000. Quantitative outcome data (Roland-Morris Disability Questionnaire [scale, 0-24] and the Numeric Rating Scale [0-10] for pain at rest and with activity) were collected immediately pre- and postoperatively and at 1 week, 1 month, 6 months, and 1 year following vertebroplasty. Patients with ≥50% improvement on the Numeric Rating Scale and ≥40% improvement on the Roland-Morris Disability Questionnaire were classified as "responders." Peri- and postoperative complications were also collected. RESULTS: Significant median improvement in the Roland-Morris Disability and rest and activity Numeric Rating Scale scores (15, 2, and 6 points, respectively; P < .0001) persisted at 1 year without significant change from the immediate postoperative scores (P > .36). Patients on systemic therapy at the time of vertebroplasty were more likely to achieve "responder status," compared with patients not on systemic therapy, for the Numeric Rating Scale pain at rest score (P < .01) and the Roland-Morris Disability Questionnaire score (P < .003), with no difference in complication rates (χ2 = 0.17, P = .68). CONCLUSIONS: Vertebroplasty is an effective therapy for patients with myeloma with symptomatic compression fractures. Favorable outcomes are more likely to be achieved when spinal augmentation is performed after systemic therapy is initiated. Complication rates were not affected by the timing of systemic therapy.
Authors: Caroline A H Klazen; Paul N M Lohle; Jolanda de Vries; Frits H Jansen; Alexander V Tielbeek; Marion C Blonk; Alexander Venmans; Willem Jan J van Rooij; Marinus C Schoemaker; Job R Juttmann; Tjoen H Lo; Harald J J Verhaar; Yolanda van der Graaf; Kaspar J van Everdingen; Alex F Muller; Otto E H Elgersma; Dirk R Halkema; Hendrik Fransen; Xavier Janssens; Erik Buskens; Willem P Th M Mali Journal: Lancet Date: 2010-08-09 Impact factor: 79.321
Authors: Ruchira M Jha; Ariel E Hirsch; Albert J Yoo; Al Ozonoff; Marion Growney; Joshua A Hirsch Journal: J Neurointerv Surg Date: 2010-09 Impact factor: 5.836
Authors: Luis Alvarez; Antonio Pérez-Higueras; Juan J Granizo; Ignacio de Miguel; Diana Quiñones; Roberto E Rossi Journal: Spine (Phila Pa 1976) Date: 2005-01-01 Impact factor: 3.468
Authors: David F Kallmes; Bryan A Comstock; Patrick J Heagerty; Judith A Turner; David J Wilson; Terry H Diamond; Richard Edwards; Leigh A Gray; Lydia Stout; Sara Owen; William Hollingworth; Basavaraj Ghdoke; Deborah J Annesley-Williams; Stuart H Ralston; Jeffrey G Jarvik Journal: N Engl J Med Date: 2009-08-06 Impact factor: 91.245
Authors: Douglas Wardlaw; Steven R Cummings; Jan Van Meirhaeghe; Leonard Bastian; John B Tillman; Jonas Ranstam; Richard Eastell; Peter Shabe; Karen Talmadge; Steven Boonen Journal: Lancet Date: 2009-02-24 Impact factor: 79.321